Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Change in Cash (2020 - 2025)

Historic Change in Cash for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to -$26.3 million.

  • Maravai Lifesciences Holdings' Change in Cash fell 62813.88% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$334.6 million, marking a year-over-year decrease of 2300656.08%. This contributed to the annual value of -$252.6 million for FY2024, which is 34172.9% down from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Change in Cash is -$26.3 million, which was down 62813.88% from -$15.1 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Change in Cash high stood at $172.9 million for Q3 2021, and its period low was -$255.8 million during Q4 2024.
  • Moreover, its 5-year median value for Change in Cash was -$571000.0 (2023), whereas its average is $388947.4.
  • Its Change in Cash has fluctuated over the past 5 years, first skyrocketed by 155069.38% in 2021, then crashed by 540846.44% in 2024.
  • Maravai Lifesciences Holdings' Change in Cash (Quarter) stood at $3.4 million in 2021, then soared by 335.45% to $14.7 million in 2022, then crashed by 131.6% to -$4.6 million in 2023, then crashed by 5408.46% to -$255.8 million in 2024, then skyrocketed by 89.7% to -$26.3 million in 2025.
  • Its Change in Cash stands at -$26.3 million for Q3 2025, versus -$15.1 million for Q2 2025 and -$37.3 million for Q1 2025.